Merus legt auf dem San Antonio Breast Cancer Symposium neue Ergebnisse zu Zenocutuzumab, Trastuzumab und Vinorelbin bei Patientinnen mit HER2-verstärktem metastasierendem Brustkrebs vor

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment